NasdaqGS - Delayed Quote USD

Agios Pharmaceuticals, Inc. (AGIO)

Compare
45.61 -2.44 (-5.08%)
At close: September 27 at 4:00 PM EDT
45.93 +0.32 (+0.70%)
After hours: September 27 at 7:42 PM EDT
Advanced Chart
Loading Chart for AGIO
DELL
  • Previous Close 48.05
  • Open 45.56
  • Bid 45.52 x 200
  • Ask 45.70 x 200
  • Day's Range 41.97 - 46.16
  • 52 Week Range 19.80 - 53.29
  • Volume 2,199,045
  • Avg. Volume 501,158
  • Market Cap (intraday) 2.595B
  • Beta (5Y Monthly) 0.75
  • PE Ratio (TTM) --
  • EPS (TTM) -6.50
  • Earnings Date Oct 31, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 57.00

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

www.agios.com

383

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Agios Pharmaceuticals, Inc.

Recent News: AGIO

View More
View More

Performance Overview: AGIO

Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AGIO
104.80%
S&P 500
20.30%

1-Year Return

AGIO
87.23%
S&P 500
34.27%

3-Year Return

AGIO
4.02%
S&P 500
28.79%

5-Year Return

AGIO
34.11%
S&P 500
92.71%

Compare To: AGIO

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

AGIO
Agios Pharmaceuticals, Inc.
45.61
-5.08%
Mkt Cap 2.595B
Industry Biotechnology
IDYA
IDEAYA Biosciences, Inc.
30.80
+0.98%
Mkt Cap 2.602B
Industry Biotechnology
CLDX
Celldex Therapeutics, Inc.
33.20
+1.03%
Mkt Cap 2.201B
Industry Biotechnology
DYN
Dyne Therapeutics, Inc.
33.83
-2.28%
Mkt Cap 3.397B
Industry Biotechnology
ARGX
argenx SE
536.11
+2.20%
Mkt Cap 32.057B
Industry Biotechnology
RNA
Avidity Biosciences, Inc.
42.33
+0.38%
Mkt Cap 5.004B
Industry Biotechnology
EWTX
Edgewise Therapeutics, Inc.
26.09
+0.38%
Mkt Cap 2.447B
Industry Biotechnology
APLS
Apellis Pharmaceuticals, Inc.
29.47
-1.27%
Mkt Cap 3.588B
Industry Biotechnology
FULC
Fulcrum Therapeutics, Inc.
3.7700
-5.75%
Mkt Cap 235.251M
Industry Biotechnology
BBIO
BridgeBio Pharma, Inc.
24.94
+1.88%
Mkt Cap 4.69B
Industry Biotechnology
CYTK
Cytokinetics, Incorporated
52.34
-0.55%
Mkt Cap 6.158B
Industry Biotechnology

Statistics: AGIO

View More

Valuation Measures

Annual
As of 9/27/2024

  • Market Cap

    2.59B

  • Enterprise Value

    2.09B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    81.92

  • Price/Book (mrq)

    3.93

  • Enterprise Value/Revenue

    66.75

  • Enterprise Value/EBITDA

    -2.33

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -27.25%

  • Return on Equity (ttm)

    -44.92%

  • Revenue (ttm)

    31.31M

  • Net Income Avi to Common (ttm)

    -364.93M

  • Diluted EPS (ttm)

    -6.50

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    569.89M

  • Total Debt/Equity (mrq)

    9.78%

  • Levered Free Cash Flow (ttm)

    -223.51M

View More

Research Analysis: AGIO

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

55.00
57.00 Average
45.61 Current
60.00 High
 
View More

Company Insights: AGIO

People Also Watch

PTCT PTC Therapeutics, Inc.
37.56
-0.27%
 
RARE Ultragenyx Pharmaceutical Inc.
54.43
-1.43%
 
BPMC Blueprint Medicines Corporation
92.55
+3.92%
 
BLUE bluebird bio, Inc.
0.5044
+1.39%
 
ALNY Alnylam Pharmaceuticals, Inc.
274.91
+0.12%
 
SAGE Sage Therapeutics, Inc.
7.29
+1.67%
 
PBYI Puma Biotechnology, Inc.
2.5800
+0.78%
 
FOLD Amicus Therapeutics, Inc.
10.71
-0.09%
 
ENTA Enanta Pharmaceuticals, Inc.
10.05
-4.01%
 
MGNX MacroGenics, Inc.
3.1900
+4.93%
 
IONS Ionis Pharmaceuticals, Inc.
40.85
-0.61%
 
ESPR Esperion Therapeutics, Inc.
1.6800
+2.44%
 
PRTA Prothena Corporation plc
20.05
-0.45%
 
HALO Halozyme Therapeutics, Inc.
56.97
+0.04%
 
KPTI Karyopharm Therapeutics Inc.
0.7239
+2.46%
 
FGEN FibroGen, Inc.
0.4064
+3.78%